Corynebacterium UTIs: Pathogenesis, Diagnosis, and Treatment

Corynebacterium species are among the most underestimated causes of urinary tract infections. For decades, clinical laboratories routinely dismissed these gram-positive bacteria as skin contaminants when they appeared in urine cultures, but a growing body of evidence shows that several Corynebacterium species are genuine urinary pathogens, particularly in hospitalized and immunocompromised patients. What makes these infections distinctive is a combination of potent urease activity, stubborn biofilm formation, and alarming levels of multidrug resistance that leave clinicians with very few antibiotic options.

Which Species Are Involved

The genus Corynebacterium contains dozens of species, but only a handful are commonly linked to urinary tract infections. The one with the longest track record is Corynebacterium urealyticum, a slow-growing, lipophilic organism that thrives in urinary environments thanks to its strong urease enzyme. A comprehensive review describes it as a multidrug-resistant, opportunistic nosocomial pathogen responsible for cystitis, pyelonephritis, and bacteremia, among other conditions.¹ But it is far from the only offender. In one study of non-diphtheriae Corynebacterium isolates from clinical samples, C. striatum was the most prevalent species (about a third of isolates), followed by C. glucuronolyticum and C. urealyticum.²

Rarer species keep turning up in the literature as well. Corynebacterium pseudogenitalium, originally isolated from the urinary tract in the late 1970s, was long considered harmless, but case reports now associate it with genuine infection.³ Even Corynebacterium mycetoides, an exceptionally rare human isolate, has been reported in a urinary infection, underscoring that the list of potential urinary pathogens within this genus continues to grow.⁴ The practical takeaway is that no Corynebacterium species recovered from urine should be reflexively dismissed without considering the clinical picture.

How They Cause Urinary Tract Disease

The central weapon in the Corynebacterium urinary toolkit is urease, an enzyme that splits urea into ammonia and carbon dioxide. Normal human urine contains plenty of urea, so a urease-producing bacterium essentially converts its surroundings into a highly alkaline environment. When C. urealyticum was inoculated into normal human urine in laboratory experiments, the pH shot up and struvite crystals formed within 24 hours.⁵ Those crystals are the building blocks of the mineral encrustations that define this organism’s most dangerous complication.

Biofilm formation adds a second layer of difficulty. Laboratory work has shown that Corynebacterium strains readily adhere to both hydrophilic surfaces like glass and polyurethane, and hydrophobic surfaces like polystyrene and silicone, though hydrophilic materials tend to support greater bacterial adhesion.⁶ This matters because urinary catheters, nephrostomy tubes, and ureteral stents are all made of materials that Corynebacterium can colonize. Studies of C. diphtheriae on polyurethane catheters, for instance, documented microcolony formation on both internal and external catheter surfaces via scanning electron microscopy, along with fibrin deposits that contributed to catheter obstruction.⁷

The combination of alkaline urine, crystal formation, and biofilm creates a self-reinforcing cycle. Once crystals embed in the bladder or kidney lining, the bacterium shelters inside the encrustation, making it nearly impossible to eradicate with antibiotics alone. Genomic analysis of C. urealyticum strains has also identified the spaDEF operon, which encodes pili, tiny hair-like structures that help the bacteria stick to host tissue.⁸ Horizontal gene transfer between strains, facilitated by a large number of transposons in the genome, may help spread virulence and resistance genes within the species.

Who Gets These Infections

C. urealyticum is a common skin colonizer in hospitalized elderly patients, especially those receiving broad-spectrum antibiotics, which wipe out competing flora and let this naturally resistant organism flourish.⁹ The typical patient profile includes some combination of older age, urinary catheterization, recent urological surgery, and underlying urological disease. Infections are reported more often in men than in women, probably because men undergo more catheterizations and urological procedures in the populations studied.

Kidney transplant recipients face especially high risk. In a prospective cohort study, roughly one in ten transplant patients (16 of 163) had C. urealyticum in their urine at baseline. Among those with the bacterium, prolonged urinary symptoms and obstructive uropathy were dramatically more frequent during follow-up.¹⁰ The immunosuppressive drugs these patients take suppress the immune response to the infection, while the transplanted ureter and bladder anastomosis provide vulnerable tissue for bacterial colonization. Left undiagnosed, the resulting encrusted pyelitis can directly threaten graft function.

Encrusted Cystitis and Encrusted Pyelitis

These are the signature complications of urease-producing Corynebacterium UTIs and deserve their own discussion because they are unlike anything caused by common urinary pathogens. Encrusted cystitis is marked by calcium phosphate and struvite deposits that coat the bladder wall, forming hard plaques embedded in chronically inflamed tissue. The condition is most frequently caused by C. urealyticum, though C. glucuronolyticum, another urea-splitting species, has also been documented as the cause in at least one case involving a previously healthy middle-aged man with no known risk factors.¹¹ That case is instructive because it shows the infection can occur outside the typical risk-factor profile.

When the infection ascends to the upper urinary tract, it becomes encrusted pyelitis, a condition where mineral deposits coat the renal pelvis and can obstruct urinary drainage. This was recognized as a severe complication in kidney transplant recipients, where the consequences include graft dysfunction and potential loss of the transplanted organ.¹² In native kidneys, encrusted pyelitis is no less threatening. Clinical observation has shown it can destroy kidney function and lead to end-stage renal failure.¹³

Why These Infections Are Hard to Diagnose

The single biggest diagnostic obstacle is that most clinical microbiology laboratories are not set up to identify Corynebacterium to the species level, and some dismiss any coryneform rods in urine as insignificant skin contaminants. Standard urine culture protocols often use media and incubation times optimized for fast-growing organisms like E. coli. C. urealyticum, by contrast, is lipophilic and slow-growing, sometimes requiring enriched media and 48 hours or more of incubation to produce visible colonies.

A South African study looking specifically for C. urealyticum on blood agar found only three isolates from nearly 8,000 urine specimens, a yield of 0.038%, and all three patients had pyuria, alkaline urine, and predisposing risk factors.¹⁴ The extremely low yield likely reflects underdetection rather than rarity. When a patient has persistent pyuria, alkaline urine, and negative standard cultures, that triad should raise suspicion for a Corynebacterium infection and prompt the lab to use appropriate media and extended incubation.

Species-level identification has historically relied on biochemical testing, but commercial biochemical panels perform poorly with Corynebacterium. Research using the CDC’s case of C. pseudogenitalium confirmed the difficulty of phenotypic identification and the need for molecular approaches when dealing with clinically relevant coryneform bacteria.³ Mass spectrometry technology has improved things considerably. In one comparison, mass spectrometry correctly identified 92% of Corynebacterium strains to the species level, significantly outperforming automated biochemical systems and manual biochemical panels.¹⁵ For cases where mass spectrometry is unavailable or results are ambiguous, 16S ribosomal RNA gene sequencing remains the gold standard for definitive identification.

Multidrug Resistance Is the Rule, Not the Exception

If there is one thing that unites clinically significant Corynebacterium species, it is their resistance to most commonly used antibiotics. A study of 1,970 clinical Corynebacterium isolates from Ontario found that susceptibility to penicillin was only about 14.5%, to erythromycin about 15%, and to clindamycin under 9%.¹⁶ These numbers are far worse than older literature suggested, and they effectively rule out the common empiric antibiotics used for most UTIs.

The resistance picture is especially bleak for C. urealyticum specifically. In one collection of 40 clinical isolates, nearly all (97.5%) were multidrug resistant, with 100% resistant to ampicillin, 95% to erythromycin, and 95% to levofloxacin. Ampicillin resistance was tied to a gene encoding a class A beta-lactamase.¹⁷ A separate analysis from Romania found that 17 out of 20 Corynebacterium strains were resistant to penicillin, cefuroxime, ceftriaxone, ciprofloxacin, and chloramphenicol simultaneously. Every strain tested was susceptible to vancomycin, teicoplanin, and linezolid, while some C. urealyticum and C. striatum isolates were sensitive only to glycopeptides and linezolid.¹⁸ Fluoroquinolone resistance in that study was linked to specific mutations in the gyrA gene.

The practical upshot is that vancomycin and linezolid are often the only reliable drugs. This is a serious limitation given that vancomycin must be given intravenously and linezolid carries risks of bone marrow suppression with prolonged use. The Ontario data confirmed this bottleneck, concluding that empiric treatment options for non-diphtheriae Corynebacterium are essentially limited to vancomycin and linezolid.¹⁶

Daptomycin Resistance as an Emerging Concern

Daptomycin, a lipopeptide antibiotic, would seem like a reasonable alternative for these multidrug-resistant organisms, but the evidence here is troubling. A multicenter study found that daptomycin nonsusceptibility emerged in 12 of 23 Corynebacterium species tested, affecting about 32% of isolates. All isolates remained susceptible to vancomycin and telavancin before and after daptomycin exposure, but the speed at which daptomycin resistance developed was alarming, occurring after a short exposure period and sometimes reaching high-level resistance.¹⁹ An earlier report on C. striatum documented the same rapid emergence in a single patient’s isolates, with vancomycin susceptibility preserved throughout.²⁰

The Ontario surveillance study also flagged a growing proportion of daptomycin-nonsusceptible isolates, at about 3% of the nearly 2,000 strains analyzed.¹⁶ Three percent does not sound like much, but in a genus where only two or three drugs work reliably, losing even one option matters. Clinicians considering daptomycin for serious Corynebacterium infections need to be aware that resistance can develop quickly during therapy and that repeat susceptibility testing may be necessary.

Treatment of Encrusted Infections

Straightforward Corynebacterium cystitis, without encrustation, can sometimes be managed with a prolonged course of an active antibiotic, usually vancomycin, guided by susceptibility testing. Chronic or encrusted infections demand a more aggressive, multimodal strategy. The approach combines three elements: targeted antibiotics to kill the bacterium, urinary acidification to dissolve or prevent further mineral deposits, and surgical or endoscopic removal of encrusted plaques and stones.²¹

A study of patients with encrusted urinary tract infections due to Corynebacterium found that all received appropriate antibiotics and most were also treated with topical urinary acidification. About 88% showed a meaningful reduction in encrusted calcifications, and kidney function improved in roughly 71%. The news was not all positive, though: poor tolerance and side effects affected 71% of patients, with secondary gram-negative urinary infections being the most common complication. At last follow-up, nearly a quarter of patients had progressed to end-stage renal disease, and one patient relapsed.²² Those numbers reflect the reality that encrusted Corynebacterium infections are a serious, potentially organ-threatening condition even with appropriate treatment.

The acidification component of treatment deserves some explanation. Because the alkaline environment is what drives crystal formation, lowering urine pH disrupts that process. This is typically done with instillation of acidic solutions directly into the bladder or renal pelvis, though oral urinary acidifiers can play a supporting role. When large encrusted stones are obstructing the urinary tract, percutaneous nephrolithotomy or endoscopic procedures are needed to remove the physical blockage before antibiotics can reach the infected tissue effectively.

Why Transplant Recipients Are Particularly Vulnerable

The prospective cohort study of kidney transplant recipients found that about 10% harbored C. urealyticum in their urine, a prevalence far higher than would be expected in a general hospital population. Among those colonized, the risks of prolonged urinary symptoms and obstructive uropathy were dramatically elevated compared to transplant patients without the bacterium.²³ The study’s authors described the infection as an underdiagnosed cause of graft dysfunction, a point worth emphasizing because the symptoms of encrusted pyelitis in a transplant kidney can mimic rejection or other causes of graft failure, leading clinicians down the wrong diagnostic path.

Transplant patients accumulate virtually every known risk factor at once: immunosuppression, broad-spectrum antibiotic prophylaxis, urinary catheterization during and after surgery, and a surgically altered urinary tract. The immunosuppressive regimen blunts the inflammatory response, which means the patient may not mount the typical symptoms of a UTI, further delaying diagnosis. By the time encrustation is visible on imaging, significant tissue damage may already have occurred.

Corynebacterium in Veterinary Settings

Urinary tract infections caused by Corynebacterium are not unique to humans. In cattle, Corynebacterium renale is a well-known cause of pyelonephritis and ureteritis. Adhesion studies have shown that C. renale preferentially attaches to epithelial cells of the vulva, followed by those of the ureter and renal pelvis, a pattern consistent with ascending infection from the lower genital tract.²⁴ A related species, C. pilosum, showed strongest adhesion to vulvar and vaginal vestibule cells but caused upper tract disease less frequently, behaving more like normal flora. The bovine model illustrates a broader principle about these bacteria: tissue tropism and adhesion capacity, not just the presence of the organism, determine whether colonization leads to disease. The same logic applies in human infections, where catheter material, host immune status, and local tissue conditions determine whether a colonizing Corynebacterium becomes a pathogen.

When to Suspect a Corynebacterium UTI

There is no single definitive sign, but a cluster of findings should raise suspicion. Persistently alkaline urine (pH above 7) in the absence of Proteus or other common urease-producing organisms is a strong clue. Pyuria with negative routine cultures is another red flag, since C. urealyticum and related species will not grow under standard culture conditions. Imaging showing bladder wall calcifications, stone formation in unusual patterns, or encrustations along a catheter or ureteral stent should prompt a specific request to the microbiology lab for extended culture on enriched media. In transplant patients, unexplained obstructive uropathy or declining graft function with no clear cause warrants consideration of this diagnosis.

The biggest clinical mistake is not thinking of these organisms in the first place. When routine culture comes back negative and the patient is not improving on empiric antibiotics, broadening the antibiotic spectrum is the reflexive move. But in Corynebacterium infections, the problem is usually not that the bug is on the resistance spectrum of standard therapy; it is that the bug was never identified to begin with. Requesting appropriate cultures is more important than escalating empiric treatment.